Answer
Belimumab reduces B-cell differentiation into antibody-producing plasma cells by binding soluble BLyS and blocking its binding to B-cell receptors, thereby inhibiting B-cell survival, including autoreactive B cells, without binding B cells directly.
Sources for this answer
- Benlysta 120 mg and 400 mg powder for concentrate for solution for infusionGlaxoSmithKline UK · emc · SmPC §5.1 Pharmacodynamic properties · Version 35Document updated
Sources checked